<DOC>
	<DOCNO>NCT00000765</DOCNO>
	<brief_summary>To evaluate safety efficacy early treatment zidovudine prevent decline CD4+ lymphocyte count patient primary HIV infection . To determine natural history virologic immunologic change primary HIV infection . Previous study indicate intervention zidovudine primary HIV infection could reduce initial viral burden subsequent decline immune function , could prolong time development AIDS also time initiation chronic antiretroviral therapy .</brief_summary>
	<brief_title>Pilot Study Evaluate Efficacy Zidovudine Preventing CD4+ Lymphocyte Decline Patients With Primary HIV Infection . ( One Treatment Arm Receives Placebo )</brief_title>
	<detailed_description>Previous study indicate intervention zidovudine primary HIV infection could reduce initial viral burden subsequent decline immune function , could prolong time development AIDS also time initiation chronic antiretroviral therapy . Patients randomize receive either zidovudine placebo daily 24 week . Patients follow development AIDS-related opportunistic infection malignancy . After week 24 , patient meet standard prescribing criterion may start FDA-approved anti-HIV therapy . After study week 48 , patient may co-enroll another clinical trial receive experimental therapy .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Medications nausea , vomit , analgesia , anxiety . Patients must : Asymptomatic symptomatic primary HIV infection , plus one follow two criterion : 1. p24 antigenemia document within 1 month prior study entry either HIV enzyme immunoassay ( IA ) negative HIV IA positive Western blot negative/indeterminate , within 1 month prior study entry . 2 . Documented seroconversion within 1 month prior study entry Western blot negative/indeterminate . Consent parent guardian le 18 year age . Exclusion Criteria Coexisting Condition : Patients follow condition exclude : poor venous access . Concurrent Medication : Excluded : Chronic steroid use . Immunomodulators . Myelosuppressive agent . Other antiretroviral agent experimental therapy ( NOTE : FDAapproved therapy permit patient qualify week 24 ; experimental therapy permit study week 48 ) .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Zidovudine</keyword>
</DOC>